Travere Therapeutics

$26.28 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Travere Therapeutics

Travere Therapeutics Inc., formerly Retrophin Inc., is a biopharmaceutical company. The Company specializing in identifying, developing and delivering therapies to people living with rare disease. It's pipeline includes sparsentan (RE-021), a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). Sparsentan is an investigational product candidate with a dual mechanism of action, selective endothelin receptor antagonist (ERA), with in vitro selectivity toward endothelin receptor type A and a potent angiotensin receptor blocker (ARB). It's pipeline also includes also include OT-58, an investigational human enzyme replacement therapy. OT-58 is being developed for the treatment of classical homocystinuria (HCU). The Company's commercial products include Chenodal, Cholbam, Thiola and Thiola EC.

Stock Analysis

last close $26.28
1-mo return 11.6%
3-mo return 102.5%
avg daily vol. 460.44T
52-week high 33.09
52-week low 12.75
market cap. $1.5B
forward pe -
annual div. -
roe -78.6%
ltg forecast -
dividend yield -
annual rev. $204M
inst own. -

Subscribe now for daily local and international financial news